Lee DSW, Rojas OL, Gommerman JL (2021) B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov 20:179–199. https://doi.org/10.1038/s41573-020-00092-2

Article  CAS  PubMed  Google Scholar 

Plosker GL, Figgitt DP (2003) Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 63:803–843. https://doi.org/10.2165/00003495-200363080-00005

Article  CAS  PubMed  Google Scholar 

Virgolini L, Marzocchi V (2004) Rituximab in autoimmune diseases. Biomed Pharmacother 58:299–309. https://doi.org/10.1016/j.biopha.2004.04.006

Article  CAS  PubMed  Google Scholar 

Marlais M, Wlodkowski T, Printza N, Kronsteiner D, Krisam R, Sauer L, Aksenova M, Ashoor I, Awan A, Bacchetta J, Balasubramanian R, Basu B, Bekassy Z, Boyer O, Chan EY, Csaicsich D, Decramer S, Dorresteijn E, Drozynska-Duklas M, Eid LA, Espinosa L, Ferraris V, Flogelova H, Forero-Delgadillo J, Gianviti A, Gracchi V, Gonzalez ML, Hansen M, Hattori M, Hong X, Hooman N, Ivanov D, Kang HG, Karava V, Kazyra I, Lungu A, Marks S, Maxted A, Moczulska A, Muller R, Nastausheva T, Parolin M, Pecoraro C, Principi I, Sanchez-Kazi C, Saygili S, Schild R, Shenoy M, Sinha R, Spizzirri AP, Stack M, Szczepanska M, Tsygin A, Tzeng J, Urbonas V, Zapata C, Zieg J, Schaefer F, Vivarelli M, Tullus K (2023) Clinical factors and adverse kidney outcomes in children with antineutrophil cytoplasmic antibody-associated glomerulonephritis. Am J Kidney Dis 81:119–122. https://doi.org/10.1053/j.ajkd.2022.05.013

Article  PubMed  Google Scholar 

Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasà M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M, Pollastro RM, Capasso G, Pisani A, Pennesi M, Emma F, Remuzzi G (2014) Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 25:850–863. https://doi.org/10.1681/ASN.2013030251

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benz K, Dötsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19:794–797. https://doi.org/10.1007/s00467-004-1434-z

Article  PubMed  Google Scholar 

Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273–1281. https://doi.org/10.1016/S0140-6736(14)60541-9

Article  CAS  PubMed  Google Scholar 

Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl’Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26:2259–2266. https://doi.org/10.1681/ASN.2014080799

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, Wetzels J, Alhasan K, Banerjee S, Bhimma R, Bonilla-Felix M, Cano F, Christian M, Hahn D, Kang HG, Nakanishi K, Safouh H, Trachtman H, Xu H, Cook W, Vivarelli M, Haffner D, International Pediatric Nephrology Association (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877–919. https://doi.org/10.1007/s00467-022-05739-3

Article  PubMed  Google Scholar 

Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, Hui NK, Boyer O, Saleem MA, Feltran L, Müller-Deile J, Becker JU, Cano F, Xu H, Lim YN, Smoyer W, Anochie I, Nakanishi K, Hodson E, Haffner D, International Pediatric Nephrology Association (2020) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 35:1529–1561. https://doi.org/10.1007/s00467-020-04519-1

Article  PubMed  PubMed Central  Google Scholar 

Floege J, Gibson KL, Vivarelli M, Liew A, Radhakrishnan J, Rovin BH (2025) KDIGO 2025 clinical practice guideline for the management of nephrotic syndrome in children. Kidney Int 107:S241–S289. https://doi.org/10.1016/j.kint.2024.11.007

Article  PubMed  Google Scholar 

Chan EY, Boyer O (2025) Childhood idiopathic nephrotic syndrome: recent advancements shaping future guidelines. Pediatr Nephrol 40:2431–2442. https://doi.org/10.1007/s00467-024-06634-9

Article  PubMed  Google Scholar 

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100:S1–S276. https://doi.org/10.1016/j.kint.2021.05.021

Article  Google Scholar 

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1-155. https://doi.org/10.1111/j.1600-6143.2009.02834.x

Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group (2024) KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int 105:S71–S116. https://doi.org/10.1016/j.kint.2023.10.008

Rovin BH, Ayoub IM, Chan TM, Liu Z-H, Mejía-Vilet JM, Floege J (2024) KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int 105:S1–S69. https://doi.org/10.1016/j.kint.2023.09.002

Article  Google Scholar 

Chan EY, Sinha A, Yu ELM, Akhtar N, Angeletti A, Bagga A, Banerjee S, Boyer O, Chan CY, Francis A, Ghiggeri GM, Hamada R, Hari P, Hooman N, Hopf LS, I MI, Ijaz I, Ivanov DD, Kalra S, Kang HG, Lucchetti L, Lugani F, Ma AL, Morello W, Camargo Muniz MD, Pradhan SK, Prikhodina L, Raafat RH, Sinha R, Teo S, Tomari K, Vivarelli M, Webb H, Yap HK, Yap DY, Tullus K (2024) An international, multi-center study evaluated rituximab therapy in childhood steroid-resistant nephrotic syndrome. Kidney Int 106:1146–1157. https://doi.org/10.1016/j.kint.2024.09.011

Article  CAS  PubMed  Google Scholar 

Chan EY, Marks SD (2025) Childhood-onset lupus nephritis: unique aspects and challenges in management. Kidney Int 108:799–810. https://doi.org/10.1016/j.kint.2025.05.039

Article  PubMed  Google Scholar 

Sellier-Leclerc A-L, Belli E, Guérin V, Dorfmüller P, Deschênes G (2013) Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol 28:1875–1879. https://doi.org/10.1007/s00467-013-2485-9

Article  PubMed  Google Scholar 

Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY (2011) Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 22:1170–1180. https://doi.org/10.1093/annonc/mdq58

Article  CAS  PubMed  Google Scholar 

Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1:e184169. https://doi.org/10.1001/jamanetworkopen.2018.4169

Article  PubMed  PubMed Central  Google Scholar 

McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, Muscal E, Lotze T, Srivaths P, Forbes LR, Allen C, Bernhardt MB (2021) Association of rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw Open 4:e2036321. https://doi.org/10.1001/jamanetworkopen.2020.36321

Article  PubMed  PubMed Central  Google Scholar 

Chan EY, Yap DY, Colucci M, Ma AL, Parekh RS, Tullus K (2023) Use of rituximab in childhood idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 18:533–548. https://doi.org/10.2215/CJN.08570722

Article  PubMed  PubMed Central  Google Scholar 

Chan EY-H, Ma AL-T, Tullus K (2022) Hypogammaglobulinaemia following rituximab therapy in childhood nephrotic syndrome. Pediatr Nephrol 37:927–931. https://doi.org/10.1007/s00467-021-05345-9

Article  PubMed  Google Scholar 

Zonozi R, Wallace ZS, Laliberte K, Huizenga NR, Rosenthal JM, Rhee EP, Cortazar FB, Niles JL (2021) Incidence, clinical features, and outcomes of late-onset neutropenia from rituximab for autoimmune disease. Arthritis Rheum 73:347–354. https://doi.org/10.1002/art.41501

Article  CAS  Google Scholar 

Otani IM, Ballow M (2025) If and when to consider prophylactic immunoglobulin replacement therapy in secondary hypogammaglobulinemia. J Allergy Clin Immunol Pract 13:511–521. https://doi.org/10.1016/j.jaip.2024.12.024

Article  PubMed  Google Scholar 

Cragg MS, Morgan SM, Chan HTC, Morgan BP, Filatov AV, Johnson PWM, French RR, Glennie MJ (2003) Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101:1045–1052. https://doi.org/10.1182/blood-2002-06-1761

Article  CAS  PubMed  Google Scholar 

Lai FF, Chan EY, Tullus K, Ma AL (2024) Therapeutic drug monitoring in childhood idiopathic nephrotic syndrome: a state of the art review. Pediatr Nephrol 39:85–103. https://doi.org/10.1007/s00467-023-05974-2

Article  PubMed